3 unknown. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Unknown 3 |
| Phase 1 | 1 | Unknown 1 |
Follow ALS: new trials by email Literature Review of ALS trials Research Report on ALS
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| NF-κB Inhibition in Amyotrophic Lateral Sclerosis Withania somnifera, Placebo - ALS | Phase 2 | Unknown | Sunnybrook Health Sciences Centre | 75 | 2021-10-19 | 2022-06-06 |
| Pharmacokinetic and Pharmacodynamic Study of AMX0035 in Patients With ALS AMX0035 - ALS | Phase 1 / Phase 2 | Unknown | Amylyx Pharmaceuticals Inc. | 14 | 2021-08-05 | 2023-07-24 |
| A Clinical Trial of Pimozide in Patients With Amyotrophic Lateral Sclerosis (ALS) Pimozide 2mg/day (current) or 4 mg/day (study initiation), Placebo Oral Tablet - ALS, Amyotrophic Lateral Sclerosis | Phase 2 | Unknown | University of Calgary | 100 | 2017-10-27 | 2020-05-28 |
Amyotrophic Lateral Sclerosis (3) · Motor Neuron Disease (1) · Nervous System Diseases (1) · Neurodegenerative Diseases (1) · Neuromuscular Diseases (1)
Central Nervous System Diseases (3) · Metabolic Diseases (3) · Nutritional and Metabolic Diseases (3) · Proteostasis Deficiencies (3) · Spinal Cord Diseases (3) · TDP-43 Proteinopathies (3) · Motor Neuron Disease (2) · Nervous System Diseases (2) · Neurodegenerative Diseases (2) · Neuromuscular Diseases (2)
Ashwagandha (1) · Pimozide (1) · sodium phenylbutyrate and taurursodiol (1)
Amylyx Pharmaceuticals Inc. (1) · Sunnybrook Health Sciences Centre (1) · University of Calgary (1)
Canada (2) · United States (1)
Agessandro Abrahao, MD, MSc (1) · Lawrence Korngut, M.D. (1) · Lorne Zinman, MD, MSc (1)